Definitions and drivers of relapse in patients with schizophrenia: A systematic literature review

Annals of General Psychiatry

Volumn 12, Issue 1, 2013, Pages

  Olivares, José M ^a   Sermon, Jan ^b   Hemels, Michiel ^c   Schreiner, Andreas ^d  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b Janssen Cilag EMEA Belgium   (Belgium)

^c Janssen Health Economics Market Access and Reimbursement   (Denmark)

^d Medical Affairs   (Germany)

Author keywords

Adherence; Definition; Drivers; Hospitalization; Relapse; Schizophrenia

Indexed keywords

OLANZAPINE; RISPERIDONE;

BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; FOLLOW UP; GLOBAL ASSESSMENT OF FUNCTIONING; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MEDICAID; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PSYCHOEDUCATION; PUBLICATION; RECURRENCE RISK; REFERENCE DATABASE; RELAPSE; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TREATMENT REFUSAL; VALIDITY;

EID: 84886075606     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-12-32     Document Type: Review

References (141)

1. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992, 20:1-97.
2. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005, 6:132-191.
3. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005, 162:441-449.
4. National Institute for Clinical Excellence Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). National Clinical Practice Guidelines Number 82 2009, 210. London: NICE, National Institute for Clinical Excellence.
5. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006, 7:5-40.
6. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161(Suppl 2):1-56.
7. Taylor M, Chaudhry I, Cross M, McDonald E, Miller P, Pilowsky L, Strickland P. Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum Psychopharmacol 2005, 20:175-181.
8. Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 2007, 68(Suppl 14):27-30.
9. Kane JM. Treatment adherence and long-term outcomes. CNS Spectr 2007, 12:21-26.
10. Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008, 26:149-162.
11. Malik N, Kingdon D, Pelton J, Mehta R, Turkington D. Effectiveness of brief cognitive-behavioral therapy for schizophrenia delivered by mental health nurses: relapse and recovery at 24 months. J Clin Psychiatry 2009, 70:201-207.
12. Muller N. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 2004, 37(Suppl 2):S141-S147.
13. Samalin L, Blanc O, Llorca PM. Optimizing treatment of schizophrenia to minimize relapse. Expert Rev Neurother 2010, 10:147-150.
14. Dixon LB, Perkins DO, Calmes C. Guideline Watch (September 2009): Practice Guideline for the Treatment of Patients with Schizophrenia. APA Practice Guidelines 2009, 1-10. Arlington: APA.
15. Bechdolf A, Knost B, Kuntermann C, Schiller S, Klosterkotter J, Hambrecht M, Pukrop R. A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. Acta Psychiatr Scand 2004, 110:21-28.
16. Bechdolf A, Kohn D, Knost B, Pukrop R, Klosterkotter J. A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in acute patients with schizophrenia: outcome at 24 months. Acta Psychiatr Scand 2005, 112:173-179.
17. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002, 346:16-22.
18. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008, 30:2378-2386.
19. Hong J, Windmeijer F, Novick D, Haro JM, Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:835-841.
20. Drake RJ, Dunn G, Tarrier N, Bentall RP, Haddock G, Lewis SW. Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. J Clin Psychiatry 2007, 68:81-86.
21. Haro JM, Novick D, Suárez D, Alonso J, Lépine JP, Ratcliffe M. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006, 26:571-578.
22. Taylor M, Currie A, Lloyd K, Price M, Peperell K. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol 2008, 22:128-131.
23. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A, Vega JC, Cuellar JA, de Castro FJ, Quintero CM, Martíin JF, Domínguez P, Ojeda JL, Cortés SS, Cala FI, Marín CG, Castro LM, Duaso MA, Albarracín JR, Vergara GN, Benítez AF, Cleries FM, Pérez-Brian JM, Aragón AB, Navarro JC, Biedma JA, de Pedro RB, González JF, López ME, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009, 24:287-296.
24. Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schiophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010, 26:501-509.
25. Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006, 28:1912-1921.
26. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55:886-891.
27. Pharoah FM, Mari JJ, Streiner D. Family intervention for schizophrenia. Cochrane Database Syst Rev 2000, 2:CD000088.
28. Gaertner I, Gaertner HJ, Vonthein R, Dietz K. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 2001, 21:305-310.
29. Hickling FW, McCallum M, Nooks L, Rodgers-Johnson P. Outcome of first contact schizophrenia in Jamaica. West Indian Med J 2001, 50:194-197.
30. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001, 158:266-269.
31. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001, 52:805-811.
32. Dyck DG, Hendryx MS, Short RA, Voss WD, McFarlane WR. Service use among patients with schizophrenia in psychoeducational multiple-family group treatment. Psychiatr Serv 2002, 53:749-754.
33. Hayhurst KP, Brown P, Lewis SW. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. J Psychopharmacol 2002, 16:169-175.
34. Novák-Grubic V, Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur Psychiatry 2002, 17:148-154.
35. de Sena EP, Santos-Jesus R, Miranda-Scippa A, Quarantini Lde C, Oliveira IR. Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. Rev Bras Psiquiatr 2003, 25:220-223.
36. Thompson EE, Neighbors HW, Munday C, Trierweiler S. Length of stay, referral to aftercare, and rehospitalization among psychiatric inpatients. Psychiatr Serv 2003, 54:1271-1276.
37. Usall J, Ochoa S, Araya S, Marquez M. Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample. Eur Psychiatry 2003, 18:282-284.
38. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004, 184:346-351.
39. Whitehorn D, Richard JC, Kopala LC. Hospitalization in the first year of treatment for schizophrenia. Can J Psychiatry 2004, 49:635-638.
40. Miettunen J, Lauronen E, Veijola J, Koponen H, Saarento O, Isohanni M. Patterns of psychiatric hospitalizations in schizophrenic psychoses within the Northern Finland 1966 birth cohort. Nord J Psychiatry 2006, 60:286-293.
41. Muirhead D, Harvey C, Ingram G. Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes. Aust N Z J Psychiatry 2006, 40:596-605.
42. Turkington D, Kingdon D, Rathod S, Hammond K, Pelton J, Mehta R. Outcomes of an effectiveness trial of cognitive-behavioural intervention by mental health nurses in schizophrenia. Br J Psychiatry 2006, 189:36-40.
43. Xiang YQ, Zhang ZJ, Weng YZ, Zhai YM, Li WB, Cai ZJ, Tan QR, Wang CY. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res 2006, 83:201-210.
44. Buckley LA, Pettit T, Adams CE. Supportive therapy for schizophrenia. Cochrane Database Syst Rev 2007, 3. CD004716.
45. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007, 23:2305-2312.
46. Valencia M, Rascon ML, Juarez F, Murow E. A psychosocial skills training approach in Mexican out-patients with schizophrenia. Psychol Med 2007, 37:1393-1402.
47. DosReis S, Johnson E, Steinwachs D, Rohde C, Skinner EA, Fahey M, Lehman AF. Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia. Schizophr Res 2008, 101:304-311.
48. Janicak PG, Wu JH, Mao L. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials. Curr Med Res Opin 2008, 24:1807-1815.
49. Rouillon F, Chartier F, Gasquet I. Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study. Eur Neuropsychopharmacol 2008, 18:646-652.
50. Zhu B, Ascher-Svanum H, Faries DE, Peng X, Salkever D, Slade EP. Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry 2008, 8:72.
51. Haro JM, Ciudad A, Alonso J, Bousoño M, Suárez D, Novick D, Gilaberte I. Remission and relapse in the outpatient treatment of patients with schizophrenia. Outcomes at 3 years. Actas Esp Psiquiatr 2008, 36:187-196.
52. Spaniel F, Vohlídka P, Kozený J, Novák T, Hrdlicka J, Motlová L, Cermák J, Höschl C. The Information Technology Aided Relapse Prevention Programme in Schizophrenia: an extension of a mirror-design follow-up. Int J Clin Pract 2008, 62:1943-1946.
53. Spaniel F, Vohlídka P, Hrdlicka J, Kozený J, Novák T, Motlová L, Cermák J, Bednarík J, Novák D, Höschl C. ITAREPS: information technology aided relapse prevention programme in schizophrenia. Schizophr Res 2008, 98:312-317.
54. Kim JH, Kim D, Marder SR. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:984-988.
55. Gasquet I, Chartier F, Tcherny-Lessenot S, Lépine JP. The European Schizophrenia Outpatient Health Outcomes Study: observational study over 36 months of the French cohort of schizophrenic outpatients treated with antipsychotics. Rev Epidemiol Sante Publique 2009, 57:25-32.
56. Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009, 25:2197-2206.
57. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10:2.
58. Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. Hum Psychopharmacol 2010, 25:37-46.
59. Crown WH, Neslusan C, Russo PA, Holzer S, Ozminkowski R, Croghan T. Hospitalization and total medical costs for privately insured persons with schizophrenia. Adm Policy Ment Health 2001, 28:335-351.
60. Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol 2002, 17:65-68.
61. Lipkovich I, Deberdt W, Csernansky JG, Buckley P, Peuskens J, Kollack-Walker S, Zhang Y, Liu-Seifert H, Houston JP. Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. J Psychiatr Res 2007, 41:305-310.
62. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006, 189:259-266.
63. Simonsen E, Friis S, Haahr U, Johannessen JO, Larsen TK, Melle I, Opjordsmoen S, Rund BR, Vaglum P, McGlashan T. Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiatr Scand 2007, 116:54-61.
64. Lee SH, Choi TK, Suh S, Kim YW, Kim B, Lee E, Yook KH. Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection. Psychiatry Res 2010, 175:195-199.
65. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008, 28:210-213.
66. Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, Rodriguez S, Gharabawi GM. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006, 67:1194-1203.
67. Bayle FJ, Misdrahi D, Llorca PM, Lancon C, Olivier V, Quintin P, Azorin JM. Acute schizophrenia concept and definition: investigation of a French psychiatrist population. Encéphale 2005, 31:10-17.
68. Gleeson JF, Rawlings D, Jackson HJ, McGorry PD. Early warning signs of relapse following a first episode of psychosis. Schizophr Res 2005, 80:107-111.
69. Kho KH, Blansjaar BA, de Vries, Babuskova D, Zwinderman AH, Linszen DH. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia-an open label study. Eur Arch Psychiatry Clin Neurosci 2004, 254:372-379.
70. Chabungbam G, Avasthi A, Sharan P. Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatry Clin Neurosci 2007, 61:587-593.
71. Knapp M, Locklear J, Jarbrink K. Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER. Curr Med Res Opin 2009, 25:1593-1603.
72. Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, Yook KH. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1231-1235.
73. Dossenbach M, Arango-Dávila C, Silva IH, Landa E, Aguilar J, Caro O, Leadbetter J, Assunção S. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005, 66:1021-1030.
74. Olivares JM, Rodriguez-Martinez A, Burón JA, Onso-Escolano D, Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008, 6:41-53.
75. de Haan L, Linszen DH, Lenior ME, de Win ED, Gorsira R. Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophr Bull 2003, 29:341-348.
76. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008, 8:32.
77. Burns T, Fiander M, Audini B. A delphi approach to characterising " relapse" as used in UK clinical practice. Int J Soc Psychiatry 2000, 46:220-230.
78. Bai YM, Ting CT, Chen JY, Chang WH, Wu B, Hung CH, Kuo LW. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007, 68:1218-1225.
79. Mottaghipour Y, Pourmand D, Maleki H, Davidian L. Expressed emotion and the course of schizophrenia in Iran. Soc Psychiatry Psychiatr Epidemiol 2001, 36:195-199.
80. Bradley GM, Couchman GM, Perlesz A, Nguyen AT, Singh B, Riess C. Multiple-family group treatment for English- and Vietnamese-speaking families living with schizophrenia. Psychiatr Serv 2006, 57:521-530.
81. Morabia A, Ten Have T, Huguelet P, Ferrero F. Assessing efficacy of chronic therapy when disease is characterized by frequent relapses: the example of schizophrenia. J Clin Epidemiol 2002, 55:350-357.
82. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev 2006, 4. CD000088.
83. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002, 16:473-484.
84. Pharoah FM, Rathbone J, Mari JJ, Streiner D. Family intervention for schizophrenia. Cochrane Database Syst Rev 2003, 4. CD000088.
85. Uçok A, Polat A, Cakir S, Genç A. One year outcome in first episode schizophrenia. Predictors of relapse. Eur Arch Psychiatry Clin Neurosci 2006, 256:37-43.
86. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003, 160:1209-1222.
87. Nuechterlein KH, Miklowitz DJ, Ventura J, Gitlin MJ, Stoddard M, Lukoff D. Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples. Psychiatry Res 2006, 144:153-166.
88. Linszen D, Dingemans P, Lenior M. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr Res 2001, 51:55-61.
89. Suzuki K, Awata S, Matsuoka H. One-year outcome after response to ECT in middle-aged and elderly patients with intractable catatonic schizophrenia. J ECT 2004, 20:99-106.
90. Suzuki K, Awata S, Takano T, Ebina Y, Shindo T, Harada N, Matsuoka H. Adjusting the frequency of continuation and maintenance electroconvulsive therapy to prevent relapse of catatonic schizophrenia in middle-aged and elderly patients who are relapse-prone. Psychiatry Clin Neurosci 2006, 60:486-492.
91. Suzuki K, Awata S, Takano T, Ebina Y, Iwasaki H, Matsuoka H. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia. Psychiatry Clin Neurosci 2005, 59:481-489.
92. Tomaras V, Mavreas V, Economou M, Ioannovich E, Karydi V, Stefanis C. The effect of family intervention on chronic schizophrenics under individual psychosocial treatment: a 3-year study. Soc Psychiatry Psychiatr Epidemiol 2000, 35:487-493.
93. Lançon C, Auquier P, Nayt G, Reine G. Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res 2000, 42:231-239.
94. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000, 2:CD000059.
95. Berglund N, Vahlne JO, Edman A. Family intervention in schizophrenia-impact on family burden and attitude. Soc Psychiatry Psychiatr Epidemiol 2003, 38:116-121.
96. Chabannes JP, Bazin N, Leguay D, Nuss P, Peretti CS, Tatu P, Hameg A, Garay RP, Ferreri M. Two-year study of relapse prevention by a new education program in schizophrenic patients treated with the same antipsychotic drug. Eur Psychiatry 2008, 23:8-13.
97. Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry 2006, 67:1942-1947.
98. Seuchter SA, Eisenacher M, Riesbeck M, Gaebel W, Köpcke W. Methods for predictor analysis of repeated measurements: application to psychiatric data. Methods Inf Med 2004, 43:184-191.
99. Montero I, Asencio A, Hernández I, Masanet MJ, Lacruz M, Bellver F, Iborra M, Ruiz I. Two strategies for family intervention in schizophrenia: a randomized trial in a Mediterranean environment. Schizophr Bull 2001, 27:661-670.
100. Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008, 69:47-53.
101. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encéphale 2002, 28:266-272.
102. Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 2006, 1:47-56.
103. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry 2007, 68:992-997.
104. Charpentier A, Goudemand M, Thomas P. Therapeutic alliance, a stake in schizophrenia. Encéphale 2009, 35:80-89.
105. Passerieux C, Caroli F, Giraud-Baro E. Persons suffering from schizophrenia and relapses. Encéphale 2009, 35:586-594.
106. Norman RM, Malla AK, McLean TS, McIntosh EM, Neufeld RW, Voruganti LP, Cortese L. An evaluation of a stress management program for individuals with schizophrenia. Schizophr Res 2002, 58:293-303.
107. Conley RR. The burden of depressive symptoms in people with schizophrenia. Psychiatr Clin North Am 2009, 32:853-861.
108. Bottai T, Cotton I, Drigeard A, Vaglio V. [Prodromes of schizophrenia recurrence. Encéphale 2009, 35(Suppl 1):S33-S40.
109. Kopelowicz A, Lopez SR, Zarate R, O'Brien M, Gordon J, Chang C, Gonzalez-Smith V. Expressed emotion and family interactions in Mexican Americans with schizophrenia. J Nerv Ment Dis 2006, 194:330-334.
110. Fortney JC, Xu S, Dong F. Community-level correlates of hospitalizations for persons with schizophrenia. Psychiatr Serv 2009, 60:772-778.
111. Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry 2009, 9:54.
112. Harman JS, Manning WG, Lurie N, Christianson JB. Association between interruptions in Medicaid coverage and use of inpatient psychiatric services. Psychiatr Serv 2003, 54:999-1005.
113. Malla AK, Norman RM, Manchanda R, McLean TS, Harricharan R, Cortese L, Townsend LA, Scholten DJ. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv 2002, 53:458-463.
114. Haro JM, Novick D, Suárez D, Ochoa S, Roca M. Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1287-1292.
115. Grossman LS, Harrow M, Rosen C, Faull R. Sex differences in outcome and recovery for schizophrenia and other psychotic and nonpsychotic disorders. Psychiatr Serv 2006, 57:844-850.
116. Essali A, Al-Haj HN, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009, 1:CD000059.
117. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 2001, 62(Suppl 5):14-17.
118. Jones C, Cormac I, Mota J, Campbell C. Cognitive behaviour therapy for schizophrenia. Cochrane Database Syst Rev 2000, 2:CD000524.
119. Pitschel-Walz G, Leucht S, Bauml J, Kissling W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia-a meta-analysis. Schizophr Bull 2001, 27:73-92.
120. Pekkala E, Merinder L. Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2002, 2:CD002831.
121. Pfammatter M, Junghan UM, Brenner HD. Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. Schizophr Bull 2006, 32(Suppl 1):S64-S80.
122. Thornley B, Adams CE, Awad G. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2000, 2:CD000284.
123. Sultana A, McMonagle T. Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev 2000, 3:CD001949.
124. Thornley B, Rathbone J, Adams CE, Awad G. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2003, 2:CD000284.
125. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006, 2:CD004578.
126. Rathbone J, McMonagle T. Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev 2007, 3:CD001949.
127. Adams CE, Awad G, Rathbone J, Thornley B. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2007, 2:CD000284.
128. Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004, 13:811-816.
129. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003, 2:CD000440.
130. Reveley MA, Libretto SE. Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone. J Clin Psychopharmacol 2004, 24:260-267.
131. Parellada E. Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations. Psychopharmacol Bull 2007, 40:82-100.
132. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161:692-699.
133. Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database Syst Rev 2007, 1:CD006329.
134. Sutton DL. Relapse signatures and insight: implications for CPNs. J Psychiatr Ment Health Nurs 2004, 11:569-574.
135. Larsen TK, Melle I, Friis S, Joa I, Johannessen JO, Opjordsmoen S, Simonsen E, Vaglum P, McGlashan TH. One-year effect of changing duration of untreated psychosis in a single catchment area. Br J Psychiatry Suppl 2007, 51:s128-s132.
136. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011, 168:603-609.
137. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
138. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Res 2011, 127:83-92.
139. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012, 379:2063-2071.
140. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophrenia Bull 2013, doi:10.1093/schbul/sbs150.
141. Kishimoto T, Masahiro N, Borenstein M. Poster Presented at ACNP: 2012 December 2-6 Florida, USA, poster number 175.